BofA Securities Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7
Bank of America Securities Sticks to Their Buy Rating for Sana Biotechnology (SANA)
Morgan Stanley Maintains Sana Biotechnology(SANA.US) With Buy Rating, Raises Target Price to $12
A Quick Look at Today's Ratings for Sana Biotechnology(SANA.US), With a Forecast Between $7 to $11
HC Wainwright & Co. Maintains Buy on Sana Biotechnology, Raises Price Target to $11
Analysts Offer Insights on Healthcare Companies: InMode (INMD) and Sana Biotechnology (SANA)
A Quick Look at Today's Ratings for Sana Biotechnology(SANA.US), With a Forecast Between $7 to $15
Sana Biotechnology Analyst Ratings
Citi Keeps Their Buy Rating on Sana Biotechnology (SANA)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sana Biotechnology (SANA), Immuneering (IMRX) and Johnson & Johnson (JNJ)
Sana Biotechnology's Promising UP421 Results and Potential Upside: A Buy Rating Affirmed
Sana Biotechnology (SANA) Receives a Buy From Morgan Stanley
H.C. Wainwright Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $8
Sana Biotechnology Analyst Ratings
JMP Securities Maintains Sana Biotechnology(SANA.US) With Hold Rating
TD Cowen Maintains Sana Biotechnology(SANA.US) With Hold Rating
H.C. Wainwright Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $8
Sana Biotechnology's Strategic Shift to Autoimmune Diseases Drives Buy Rating Despite Lowered Price Target
Citi Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $15
BofA Securities Initiates Sana Biotechnology(SANA.US) With Buy Rating